Amr Kouchouk
Ophthalmology · Torrance, CANPI 1639499718
Payments from drug & device makers
Across 1,054 payments — averaging $315.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$185K
- Bausch & Lomb Americas Inc.$34K
- Alcon$21K
- AbbVie$20K
- Glaukos Corporation$20K
- Oyster Point Pharma, Inc.$19K
- plus $34K from 32 others
What the payments were for
- Consulting fees$29,6939%
- Speaking & faculty fees$227,00770%
- Travel & lodging$25,8558%
- Food & beverage$39,76912%
- Charitable contribution$5000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$180,857
- MIEBO$30,343
- XIIDRA$27,318
- TRYPTYR$20,173
- TYRVAYA$17,914
- RESTASIS MULTIDOSE$6,563
- RESTASIS$6,103
- VERACITY SURGICAL$2,983
- QUATERA 700$2,644
- LOTEMAX SM$2,515
- LUMIGAN$2,473
- VisuMax$2,433
- LIPIFLOW SYSTEM ACTIVATOR (DISPOSABLE)$2,340
- KXL System$2,287
- iStent inject Trabecular Micro-Bypass Stent System$1,625
- Tecnis Simplicity$1,560
- iAccess Precision Blade$1,500
- Flarex$1,250
- ARTEVO 800$1,058
- BROMSITE$789
How this compares
$332,196 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CequaCyclosporine | 591 | $396,214 |
| MieboPerfluorohexyloctane/Pf | 220 | $192,956 |
| LumiganBimatoprost | 568 | $157,527 |
| XiidraLifitegrast | 191 | $154,387 |
| RestasisCyclosporine | 148 | $101,611 |
| TyrvayaVarenicline Tartrate | 120 | $87,188 |
| XdemvyLotilaner | 39 | $72,556 |
| Cyclosporine | 119 | $40,322 |
| EysuvisLoteprednol Etabonate | 48 | $23,419 |
| CombiganBrimonidine Tartrate/Timolol | 97 | $22,817 |
| VyzultaLatanoprostene Bunod | 50 | $18,948 |
| Prednisolone Acetate | 476 | $12,781 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 114 | $12,223 |
| RhopressaNetarsudil Mesylate | 25 | $11,351 |
| RocklatanNetarsudil Mesylat/Latanoprost | 29 | $9,315 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sun Pharmaceutical Industries Inc.Cequa | $184,911 | $396,214591 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta | $34,322 | $366,290461 claims |
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $19,574 | $286,755835 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $19,167 | $87,188120 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $629 | $72,55639 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $598 | $23,41948 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $127 | $20,66654 claims |
| AlconSimbrinza, Azopt | $20,540 | $12,63640 claims |
| Eyevance Pharmaceuticals LLCTobradex St | $1,342 | $7,07731 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Torrance
- Damien GoldbergTorrance$4.1M
- Mehran TabanTorrance$893K
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.